Foghorn Therapeutics (FHTX) Operating Expenses (2019 - 2026)

Foghorn Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 13.94% year-over-year to $24.8 million in Q1 2026; TTM through Mar 2026 was $113.3 million, a 6.31% decrease from a year earlier, with the FY2025 full-year figure at $117.3 million, down 6.38% from the prior year.
• Operating Expenses fell to $24.8 million in Q1 2026 per FHTX's latest filing, from $33.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $38.6 million in Q1 2023 and bottomed at $24.8 million in Q1 2026.
• The 5-year median for Operating Expenses is $33.1 million (2025), against an average of $32.1 million.
• Across the five-year window, Operating Expenses surged 43.07% in 2022 and decreased 15.81% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $36.1 million in 2022, then decreased by 13.43% to $31.2 million in 2023, then dropped by 13.98% to $26.9 million in 2024, then increased by 23.32% to $33.1 million in 2025, then decreased by 25.01% to $24.8 million in 2026.
• Per Business Quant, the three latest FHTX Operating Expenses figures stand at $24.8 million (Q1 2026), $33.1 million (Q4 2025), and $26.7 million (Q3 2025).